
IGM Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
- Initial data from Phase 1 trial of IGM-2323 in relapsed/refractory non-Hodgkin’s lymphoma expected in the second half of 2020 - - IND filing for IGM-8444 planned in 2020 - - Company to host conference call today at 4:30 p.m. ET - MOUNTAIN VIEW, Calif., …